alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           4,631
<SECURITIES>                                         0
<RECEIVABLES>                                   57,564
<ALLOWANCES>                                   (3,184)
<INVENTORY>                                     17,439
<CURRENT-ASSETS>                                80,333
<PP&E>                                         138,227
<DEPRECIATION>                                (48,136)
<TOTAL-ASSETS>                                 219,720
<CURRENT-LIABILITIES>                           39,788
<BONDS>                                        210,936
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            91
<OTHER-SE>                                    (34,242)
<TOTAL-LIABILITY-AND-EQUITY>                   219,720
<SALES>                                         62,061
<TOTAL-REVENUES>                                62,061
<CGS>                                           33,396
<TOTAL-COSTS>                                   51,383
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               7,169
<INCOME-PRETAX>                                  3,509
<INCOME-TAX>                                       197
<INCOME-CONTINUING>                              3,312
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,312
<EPS-BASIC>                                       0.27
<EPS-DILUTED>                                     0.21


</TABLE>
No. 57174.

protests 841228-G, etc. (New York).

#### Berg Fur Co. *v.*United States,

Opinion by

Oliver, C. J.

In accordance with stipulation of counsel that the kidskin plates are similar in all material respects to those the subject of *Kung Chen Fur Corpn.*v. *United States*(29 Cust. Ct. 266; C. D. 1480), the claim for free entry under paragraph 1681 was sustained.

Ford, J., concurred.

Mollison, J., dissented for the reasons set forth in his dissenting opinion in C. D. 1480, *supra.*
Electronically FiledIntermediate Court of AppealsCAAP-11-000002918-FEB-201110:48 AM
No. 55107.

#### The Gruen Watch Company *v.*United States,

protests 127366-K and 128993-K (Cleveland).

*330Opinion by

Ekwall, J.

It was stipulated that the appraisement of the merchandise and the liquidation of the entries were made in the same manner, under facts and circumstances the same in all material respects, as the appraisement and liquidation in *The Gruen Watch Company*v. *United States*(24 Cust. Ct. 101, C. D. 1216). In accordance with stipulation and following the cited authority the claim of the plaintiff was sustained. It was further held that a legal liquidation should be had which would form the basis for a protest in which, should it so desire, the importer may litigate any questions presented by such action under section 514, Tariff Act of 1930.
No. 60401.

protests 239188-K, etc. (New York).

#### Astra Trading Corp. et al. *v.*United States,

Opinion by

Wilson, J.

In accordance with stipulation of counsel that the issues are the same in all material respects as those the subject of *John P. Herber & Co., Inc.*v. *United States*(30 Cust. Ct. 193, C. D. 1519), the protests were dismissed, and the matters were remanded to a single judge sitting in reappraisement for determination of the value of the merchandise in the manner provided by law (28 U. S. C. § 2636 (d)).
No. 65368.

#### Zaloom Bros. Co. *v.*United States,

protests 317153-K, 317154-K, and 317161-K (New York).

Opinion by

Donlon, J.

In accordance with stipulation of counsel that the merchandise and issues are similar in all material respects to those involved in *United States*v. *The Best Foods, Inc.*(47 C.C.P.A. 163, C.A.D. 751), the claim of the plaintiff was sustained.
Order entered December 31, 2018

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05
- 18
- 01485
- CV DANIEL K. HAGOOD, P. C. AND FITZPATRICK H AGOOD SMITH AND UHL, LLP, Appellant s V. KUNAL KAPAI, Appellee On Appeal from the County Court at Law No. 4

Dallas County, Texas Trial Court Cause No. CC
- 18
- 04027
- D



### O RDER
Befo re the Court is appellants’ December 21, 2018 first unopposed motion for extension
of time to file brief

. Because this is an accelerated appeal, we GRANT the motion to the extent

we ORDER the brief be filed no later than January 29, 2019. We caution that further extension requests will be disfavored.

/s/ DAVID EVANS JUSTICE
Index of Records Available for Gulf West Landfill – Anahuac, TX (RCRA-2010-1052) Proposed Rule

1. Sampling and Analysis Plan

Sampling and Analysis Plan for Gulf West Landfill TX LP, Chambers County , Texas, 

November 2008 (Attachment B of the Delisting Petition) 

Sampling and Analysis Plan and QAPP Approval by EPA Region 6 (PDF) (1pp, 168 KB), 

filename : Approval Dec 2008.pdf ) 

Sampling and Analysis Plan, Revised - June 2008 (Hard Copy) 

EPA Comments on Sampling and Analysis Plan, July 2008 (PDF) (2 pp, 535KB, 

filename: SAP comments 708.pdf )

2. Delisting Petition

Delisting Petition Gulf West Landfill Leachate, December 2009 (PDF) (1050 pp, 12.7M, 

filename:Delisting Petition Gulf West R5.pdf) 

3. Delisting Risk Assessment Software Run

DRAS Run – Landfill Leachate (PDF) (6 pp, 50 KB, filename:Gulf West Landfill DRAS ) 

Surface Impoundment Correction (PDF) (3 pp, 71 KB, filename: Allied SI Correction.pdf) 

4. Delisting Risk Assessment Software Technical Support Documents (documents can be 

found on the internet at http://www.epa.gov/reg5rcra/wptdiv/hazardous/delisting/drassoftware.html) 

Chapter 1: Introduction (PDF) (35pp, 260k)

Chapter 2: Estimation of Chemical Releases and Media Concentrations (PDF) (47pp, 862k)

Chapter 3: Exposure Scenario Selection (PDF) (14pp, 125k)

Chapter 4: Quantitative Estimation of Risk (PDF) (89pp, 1.6M)

Chapter 5: Uncertainty (PDF) (9pp, 61k)

Chapter 6: References (PDF) (8pp, 60K)

Appendix A: Appendix with Chemical Data for Waste Constituents in DRAS (PDF) (562pp, 

4M)

Appendix A-1b: Appendix with Chemical Data for Waste Constituents in DRAS (PDF) 

(147pp, 1M)

Appendix A2: Appendix with National Primary Drinking Water Standards (PDF) (3pp, 42K)

Appendix A3: Appendix with Soil Saturation Values (PDF) (7pp, 65K)

Appendix A4: Target Organs and Critical Effects for Compounds with Reference Doses 

(PDF) (10pp, 187K)

Appendix A5: Appendix with Default Variables: Abbreviations, Units and Values (3pp,42K)
EXHIBIT 32(II)

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      In connection with the annual report on Form 10-KSB of Dialog Group,  Inc.
(the  "Company")  for the  quarter  ended  March  31,  2004 as  filed  with  the
Securities  and  Exchange  Commission  on the date  hereof (the  "Report"),  the
undersigned,  Vincent  DeCrescenzo,  Sr.,  the Chief  Financial  Officer  of the
Company, hereby certifies, pursuant to 18 U.S.C. section 1350, that:

      (1) the Report fully  complies with the  requirements  of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

      (2) the  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.

Dated: May 14, 2004

                                                      /S/ VINCENT DECRESCENZO
                                                    ----------------------------
                                                    Vincent DeCrescenzo, Sr. CFO
Exhibit 99.1

                               THE GSI GROUP, INC.
                             1004 E. Illinois Street
                           Assumption, Illinois  62510



November  8,  2002

Securities  and  Exchange  Commission
450  Fifth  Street,  N.W.
Washington,  D.C.  20549

Re:     Certification  pursuant  to  18  U.S.C.   1350,
     as  enacted  by  Section  906  of  the  Sarbanes-Oxley  Act  of  2002
     ---------------------------------------------------------------------

Ladies  and  Gentlemen:
     In  connection with the Quarterly Report on Form 10-Q for the quarter ended
September  27,  2002  of  The  GSI  Group,  Inc.,  a  Delaware  corporation (the
"Company"), filed with the Securities and Exchange Commission on the date hereof
(the "Report"), the undersigned hereby certify, pursuant to 18 U.S.C.   1350, as
enacted  by  section  906  of  the  Sarbanes-Oxley  Act  of  2002,  that:
1.     The Report fully complies with the requirements of Section 13(a) or 15(d)
of  the  Securities  Exchange  Act  of  1934,  and
2.     The  information contained in the Report fairly presents, in all material
respects,  the  financial  condition  and  results of operations of the Company.


     /s/  Craig  Sloan
Craig  Sloan
Chief  Executive  Officer



     /s/  Russell  C.  Mello
Russell  C.  Mello
Chief  Financial  Officer,
Secretary  and  Treasurer
Exhibit 32

  Certification of Principal Executive Officer and Principal Financial Officer
                             18 U.S.C. Section 1350
                             as Adopted Pursuant to
                  Section 906 of the Sarbanes-Oxley Act of 2002



The undersigned, the Principal Executive Officer (President) and the Principal
Financial Officer (CFO) of GLOBAL BIOTECH CORP. (the "Company"), hereby
certifies that to his knowledge on the date hereof:

        (a)     The Annual Report on Form 10-K SB of the Company for the year
                ended November 30, 2008, filed on the date hereof with the
                Securities and Exchange Commission (the "Report") fully complies
                with the requirements of Section 13(a) or 15 (d) of the
                Securities Exchange Act of 1934; and
        (b)     Information contained in the Report fairly presents, in all
                material respects, the financial condition and results of
                operations of the Company.


Date: February 27,2009

                                                                 /s/ Louis Greco
                                                                 ---------------
                                                           Louis Greco,President
                                                   (Principal Executive Officer)


                                                             /S/ Perry Choiniere
                                                             -------------------
                                                                 Perry Choiniere
                                                         Chief Financial Officer



This certification accompanies the Report pursuant to the Sarbanes-Oxley Act of
2002 and shall not, except to the extent required by such Act, be deemed filed
by the Company for purposes of Section 18 of the Securities Exchange Act of
1934, as amended.
gwph-ex1048_129.htm



 

EXHIBIT 10.48

February [●], 2021     

 

 

[Executive Name]

c/o last address on file with the Company

 

 

Transition Incentive Bonus Opportunity

 

 

Dear [Executive Name]:

 

Reference is made to the Transition Agreement, dated as of February 3, 2021 (the “Transition Agreement”), by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals plc (“Jazz”) and GW Pharmaceuticals plc (the “Company”), pursuant to which the Company will be acquired by Jazz.  

In order to retain and incentivize you during this important time given your critical role with the Company and your expected important role in connection with the integration of the Company with Jazz following the Effective Time (as defined in the Transition Agreement), the Company hereby grants you a special transition incentive bonus opportunity in an amount equal to $[●] (the “Transition Incentive Bonus”), subject to the terms set forth below.  

Subject to the consummation of the transitions contemplated by the Transition Agreement, the Transition Incentive Bonus will be paid to you within 30 days following the later of December 31, 2021 or six (6) months following the Effective Time (as defined in the Transition Agreement) (the later of such dates, the “Payment Date”), subject to your continued employment, and except in circumstances amounting to a Qualifying Termination as described in the following sentence, you not having served notice to terminate your employment with Jazz, the Company or any of their respective subsidiaries at such time.  Prior to the Payment Date, in the event of your death, Disability or a Qualifying Termination (each such term as defined in the Amended and Restated Greenwich Biosciences, Inc. Change in Control Severance Plan GW UK Change in Control and Severance Benefit Plan, you will receive earlier payment of the Transition Incentive Bonus within 30 days following any such event, subject to (other than in the case of your death) your execution of the release of claims referenced in the [Amended and Restated Greenwich Biosciences, Inc. Change in Control Severance Plan] [GW UK Change in Control and Severance Benefit Plan] and such release becoming effective and irrevocable.  

The Transition Incentive Bonus will be paid in cash in a lump sum, net of any withholding or other legally required deductions.  The Transition Incentive Bonus will not be treated as salary or taken into account for purposes of determining any other compensation or benefits that may be provided to you.  Nothing herein shall constitute an employment contract or agreement or a guarantee of continued employment.

We thank you for your dedicated service and look forward to your continued service during this exciting time.  

 

 

]

 



 

Very truly yours,

 

[Greenwich biosciences, inc.]

[GW PHARMACEUTICALS plc]

 

By:

Name:

Title:

 

 

Acknowledged and accepted:
vir-ex1051_886.htm



Exhibit 10.51

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,    MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT                   MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY         DISCLOSED.

 

SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment 2”), entered into as of September 28th, 2020 (the “Amendment Date”), and effective as of the Effective Date, is made and entered into by and between The Rockefeller University, a New York not-for-profit education corporation, with a principal place of business at 1230 York Avenue, New York, NY 10065 (“Rockefeller”, also referred to herein as “Licensor”) and Vir Biotechnology, Inc. a Delaware corporation, with a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (referred to herein as “Licensee”).

WHEREAS, Licensor and Licensee entered into a certain Exclusive License Agreement, effective as of July 31, 2018 (the “Agreement”, as amendment by Amendment dated May 17th, 2019); and

WHEREAS, the parties wish to amend the Agreement to include additional intellectual property developed at Rockefeller under a Collaborative Research Agreement dated as of April 1, 2017 between the parties.

NOW THEREFORE, in consideration of the mutual obligations contained in this Agreement, and intending to be legally bound, the parties agree as follows:


	
 
	
1.
	
Amendment. The Exhibit-B of the License Agreement will be deleted and replaced with the following:




EXHIBIT B
Licensed Patents

- [***]

- [***]


	
 
	
2.
	
All provisions of the Agreement not expressly modified by this Amendment shall remain in full force and effect.





	
 
	
3.
	
This Amendment may be executed in counterparts with the same effect as if each of the Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Signatures to this Amendment transmitted by facsimile, by email in “portable document format” (“.pdf”), or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Amendment shall have the same effect as physical delivery of the paper document bearing original signature.




 



 

(Signature page follows)

2



Exhibit 10.51

 

 

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Date.

 


	
VIR BIOTECHNOLOGY, INC.:
	
 
	
THE ROCKEFELLER UNIVERSITY:

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
BY:
	
 
	
/s/ Jay Parrish
	
9/29/2020
	
 
	
BY:
	
 
	
/s/ Jeanne Ferrell
	
9/28/2020

	
NAME:
	
 
	
Jay Parrish
	
 
	
NAME:
	
 
	
Jeanne Farrell, PhD

	
TITLE:
	
 
	
CBO
	
 
	
TITLE:
	
 
	
Associate VP Technology Transfer

	
 
	
 
	
 
	
 
	
 
	
 
	
 




 

[Signature Page to Amendment to Exclusive License Agreement]
No. 51595.

#### Protests 989941-G, etc., of F. Weintraub & Co. of N. Y., Inc. (New York).

Opinion by

Oliver, P. J.

It was stipulated that the merchandise consists of beads similar in all material respects to those the subject of *Eitinger Bead Co., Inc.*v. *United States*(17 Cust. Ct. 56, C. D. 1020) and *Eitinger Bead Co.*v. *United States*(13 Cust. Ct. 50, C. D. 867). In accordance therewith the claim at 35 percent under paragraph 1503, or at 20 percent under the same paragraph, as modified by T. D. 49458, was sustained.
`[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[H.J. Res. 44 Reported in House (RH)]






                                                  Union Calendar No. 61
106th CONGRESS
  1st Session
H. J. RES. 44

                          [Report No. 106-115]

 Declaring a state of war between the United States and the Government 
                 of the Federal Republic of Yugoslavia.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             April 12, 1999

   Mr. Campbell introduced the following joint resolution; which was 
          referred to the Committee on International Relations

                             April 27, 1999

       Additional sponsors: Mr. Goodling and Mr. Barr of Georgia

                             April 27, 1999

   Reported adversely from the Committee on International Relations, 
   committed to the Committee of the Whole House on the State of the 
                    Union, and ordered to be printed

_______________________________________________________________________

                            JOINT RESOLUTION


 
 Declaring a state of war between the United States and the Government 
                 of the Federal Republic of Yugoslavia.

    Resolved by the Senate and House of Representatives of the United 
States of America in Congress assembled, That pursuant to section 5(b) 
of the War Powers Resolution (50 U.S.C. 1544(b)), and article 1, 
section 8 of the United States Constitution, a state of war is declared 
to exist between the United States and the Government of the Federal 
Republic of Yugoslavia.
                                     





                                                  Union Calendar No. 61

106th CONGRESS

  1st Session

                             H. J. RES. 44

                          [Report No. 106-115]

_______________________________________________________________________

                            JOINT RESOLUTION

 Declaring a state of war between the United States and the Government 
                 of the Federal Republic of Yugoslavia.

_______________________________________________________________________

                             April 27, 1999

   Reported adversely from the Committee on International Relations, 
   committed to the Committee of the Whole House on the State of the 
                    Union, and ordered to be printed`
IN THE UNITED STATES DISTRICT COURT 


FOR THE EASTERN DISTRICT OF PENNSYL VANIA 


CAROLINE BEHREND, et al. 	 CIVIL ACTION FILED 

v. 

JUL 16 2012 

COMCAST CORPORATION, et al. 	 NO. 03-6604 MICHAEL E. I<UNZ, Clerk 

By Oep. Clerk 

ORDER 


AND NOW, this 16th day of July, 2012, IT IS HEREBY ORDERED as follows: 


1. Plaintiffs' Motion to Maintain Motion to Enforce Settlement Papers Under Seal and 

for Show Cause Order (Docket Entry No. 514) is GRANTED IN PART. 

A. 	 All settlement papers are to be maintained under seal pending further order 

of the court. 

B. 	 The portion of the motion seeking an order to show cause is DENIED with 

leave to reassert after adjudication of Plaintiffs' Motion to Enforce 

Settlement. 

2. Plaintiffs' Motion for Leave to File Reply Brief (Docket Entry No. 520) IS 

GRANTED. 

John RPadova, 1. 

Case 2:03-cv-06604-JP Document 522 Filed 07/16/12 Page 1 of 1
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 18-1082

SIERRA CLUB; VIRGINIA WILDERNESS COMMITTEE,

Petitioners,

v.

UNITED STATES DEPARTMENT OF THE INTERIOR; NATIONAL PARK 

SERVICE, an agency of the U.S. Department of the Interior; RYAN ZINKE, 

in his official capacity Secretary of the Department of the Interior; 

MICHAEL T. REYNOLDS, in his official capacity as Deputy Director, 

Operations, Exercising the Authority of Director; STAN AUSTIN, in his official 

capacity as Southeast Regional Director, Responsible Official,

Respondents,

ATLANTIC COAST PIPELINE, LLC,

Intervenor.

No. 18-1083

DEFENDERS OF WILDLIFE; SIERRA CLUB; VIRGINIA WILDERNESS 

COMMITTEE,

Petitioners,

v.

UNITED STATES DEPARTMENT OF THE INTERIOR; FISH AND WILDLIFE 

SERVICE, an agency of the U.S. Department of the Interior; RYAN ZINKE, in his 

official capacity Secretary of the Department of the Interior; GREG SHEEHAN, in 
2

his official capacity as Principal Deputy Director; CINDY SCHULZ, in her official 

capacity as Field Supervisor, Virginia Ecological Services, Responsible Official,

Respondents,

ATLANTIC COAST PIPELINE, LLC,

Intervenor.

On Petition for Review from the United States Department of the Interior. (5-140-1945)

Argued: May 10, 2018 Decided: May 15, 2018

Before GREGORY, Chief Judge, WYNN and THACKER, Circuit Judges.

ARGUED: Austin Donald Gerken, Jr., SOUTHERN ENVIRONMENTAL LAW 

CENTER, Asheville, North Carolina, for Petitioners. Avi Kupfer, UNITED STATES 

DEPARTMENT OF JUSTICE, Washington, D.C., for Respondents. Brooks Meredith 

Smith, TROUTMAN SANDERS LLP, Richmond, Virginia, for Intervenor. ON BRIEF: 

Amelia Burnette, J. Patrick Hunter, Asheville, North Carolina, Gregory Buppert, 

SOUTHERN ENVIRONMENTAL LAW CENTER, Charlottesville, Virginia, for 

Petitioners. Eric Grant, Deputy Assistant Attorney General, Andrew Mergen, J. David 

Gunter II, Environment and Natural Resources Division, UNITED STATES 

DEPARTMENT OF JUSTICE, Washington, D.C.; Andrew Tittler, S. Amanda Bossie, 

Office of the Solicitor, DEPARTMENT OF THE INTERIOR, Washington, D.C., for 

Respondents. Andrea W. Wortzel, TROUTMAN SANDERS LLP, Richmond, Virginia, 

for Intervenor.

ORDER
3

PER CURIAM:

Petitioners seek review of the U.S. Fish and Wildlife Service’s Incidental Take 

Statement, which authorized the Atlantic Coast Pipeline project to take certain threatened 

or endangered species. As to five of the affected species, Petitioners argue that the 

agency failed to set clear limits on take as required by the Endangered Species Act.

Exercising jurisdiction pursuant to 15 U.S.C. § 717r(d)(1), we conclude, for 

reasons to be more fully explained in a forthcoming opinion, that the limits set by the 

agency are so indeterminate that they undermine the Incidental Take Statement’s 

enforcement and monitoring function under the Endangered Species Act. Accordingly, 

we VACATE the Fish and Wildlife Service’s Incidental Take Statement. See 5 U.S.C. 

§ 706(2). We reserve judgment on the parties’ remaining disputes until our forthcoming 

opinion.

IT IS SO ORDERED.